OSE Immunotherapeutics SA and the FoRT Foundation announced last week that the first patient was randomized to receive treatment in the phase 2 trial of Tedopi and Opdivo (nivolumab).
The combination therapy will be given as a second-line treatment to patients with HLA-A2-positive metastatic non-small cell lung cancer (NSCLC). Patients will be randomized to receive either Tedopi and Opdivo – which is a PD-1 targeted checkpoint immune inhibitor – , Tedopi plus chemotherapy or chemotherapy alone.
Tedopi is a neo-epitope-based vaccine that activates T lymphocytes, which researchers hope will optimize the checkpoint inhibitor or chemotherapy in patients who have become resistant.
“We look forward to evaluating this second-line combination of immuno-therapeutic agents in NSCLC patients with disease progression, a population who needs new treatment options,” said Dr. Federico Cappuzzo, director of medical oncology at Cancer Institute Regina Elena, in a release.
The trial will have 105 patients, and results are expected in 2024.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
